Previous 10 | Next 10 |
2023-04-10 08:26:10 ET Summary GSK's dividend yield is 3.58%, slightly higher than Bristol-Myers Squibb's 3.22%. Bristol-Myers Squibb's total debt was about $40.8 billion at the end of 2022, down $4.78 billion from the previous year, thanks to the successful integration of Celgene...
2023-04-10 07:33:47 ET Regeneron Pharmaceuticals ( NASDAQ: REGN ) said on Monday that its Q1 acquired in-process research and development charges will be ~$56M on a pretax basis. The charge is related to an up-front payment for collaboration and license agreement with Son...
2023-04-09 09:30:00 ET Following last year's downturn, history suggests that things will be much better for investors as bear markets rarely happen two years in a row. So far -- even with economic concerns and a potential recession looming -- 2023 is proving to be pretty good for equi...
2023-04-09 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
TARRYTOWN, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its first quarter 2023 financial and operating results on Thursday, May 4, 2023, before the U.S. financial markets open. The Company will host a conference c...
2023-03-30 17:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-03-30 07:17:56 ET Xeris Biopharma Holdings ( NASDAQ: XERS ) announced Thursday an agreement with Regeneron Pharmaceuticals ( REGN ) to use its drug-formulation platform, XeriJect, to develop monoclonal antibodies for subcutaneous delivery. Per the terms, Chicago, ...
2023-03-30 05:48:00 ET On March 23, Sanofi (NASDAQ: SNY) and Regeneron 's (NASDAQ: REGN) Dupixent shared positive results in its phase 3 clinical trial of patients with uncontrolled, chronic obstructive pulmonary disease (COPD). With no novel treatments approved in over ...
2023-03-29 07:31:48 ET The European Commission (EC) approved the expanded use of Regeneron Pharmaceuticals' ( NASDAQ: REGN ) Libtayo in combination with platinum-based chemotherapy as a first-line therapy for adult patients with advanced non-small cell lung cancer (N...
Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed to include patients with varied disease presentations seen in everyday clinical practice Approval marks second first-line indication in NSCLC and fifth indication f...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...